International Stem Cell Corp., a California-based biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), just announced that amendments have been made to its license agreements with Advanced Cell Technology, Inc.
First entered into in 2004, the license agreements provide access to an array of patents and patent applications for the use of various technologies in certain human tissues.
Through these amendments, ISCO has extended its existing rights in the area of parthenogenesis, as well as the therapeutic use of parthenogenetically derived stem cells for treating any human diseases. ISCO now has an exclusive worldwide license to ACT’s patents and applications covering the uses of parthenogenetically derived stem cells in generating human tissue.
“We’re excited to have extended our portfolio of intellectual property which not only allows us to develop new therapeutic and business opportunities, but also makes the possibility of partnering with big pharma practical,” commented Dr. Andrey Semechkin, CEO and Co-Chairman of ISCO.
For more information, visit www.internationalstemcell.com
Let us hear your thoughts below: